Imidazotriazine derivatives as il-17 modulators

A compound of formula (I) or an N-oxide thereof, or a pharmaceutically acceptable salt thereof:

• wherein
• E represents a group of formula (Ea), (Eb), (Ec), (Ed) or (Ee):
• in which the asterisk (*) represents the point of attachment to the remainder of the molecule;
• ring A represents C3-7 cycloalkyl or C3-7 heterocycloalkyl, either of which groups may be optionally substituted by one or more substituents;
• R1 represents hydrogen, fluoro, chloro, methyl, difluoromethyl or trifluoromethyl;
• R6 represents —OR6a or —NR6bR6c;
• or R6 represents C1-6 alkyl, C3-9 cycloalkyl, C3-9 cycloalkyl(C1-6)alkyl, aryl, aryl(C1-6)alkyl, C3-7 heterocycloalkyl, C3-7 heterocycloalkyl-(C1-6)alkyl, heteroaryl or heteroaryl(C1-6)alkyl, any of which groups may be optionally substituted by one or more substituents;
• R6a represents C1-6 alkyl;
• or R6a represents C3-9 cycloalkyl or C3-7 heterocycloalkyl, either of which groups may be optionally substituted by one or more substituents;
• R6b represents hydrogen or C1-6 alkyl;
• and
• R6c represents hydrogen or C1-6 alkyl;
• or
• R6b and R6c, when taken together with the nitrogen atom to which they are both attached, represent azetidin-1-yl, pyrrolidin-1-yl, oxazolidin-3-yl, isoxazolidin-2-yl, thiazolidin-3-yl, isothiazolidin-2-yl, piperidin-1-yl, morpholin-4-yl, thiomorpholin-4-yl, piperazin-1-yl, homopiperidin-1-yl, homomorpholin-4-yl or homopiperazin-1-yl, any of which groups may be optionally substituted by one or more substituents.